Q3 EPS Estimate for Cadrenal Therapeutics Cut by Analyst

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Equities researchers at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Cadrenal Therapeutics in a research report issued to clients and investors on Friday, August 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.93) for the quarter, down from their previous forecast of ($0.65). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($4.01) per share. HC Wainwright also issued estimates for Cadrenal Therapeutics’ Q4 2026 earnings at ($0.87) EPS, FY2026 earnings at ($3.92) EPS, FY2027 earnings at ($3.26) EPS and FY2028 earnings at ($1.92) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.28.

Several other research firms have also weighed in on CVKD. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $13.00.

Cadrenal Therapeutics Price Performance

Shares of CVKD opened at $1.76 on Tuesday. The company has a market capitalization of $6.02 million, a price-to-earnings ratio of -0.36 and a beta of 1.84. Cadrenal Therapeutics has a fifty-two week low of $1.71 and a fifty-two week high of $14.64. The business’s 50-day moving average is $2.66 and its 200-day moving average is $4.76.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in Cadrenal Therapeutics during the third quarter worth $103,000. Citadel Advisors LLC acquired a new stake in Cadrenal Therapeutics in the 3rd quarter valued at about $274,000. Geode Capital Management LLC increased its stake in shares of Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares during the period. Finally, DRW Securities LLC acquired a new position in Cadrenal Therapeutics during the 4th quarter valued at about $171,000. 7.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Quang X. Pham sold 9,029 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $3.05, for a total value of $27,538.45. Following the transaction, the chief executive officer directly owned 105,989 shares of the company’s stock, valued at approximately $323,266.45. This trade represents a 7.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 87,726 shares of company stock valued at $333,575. 14.59% of the stock is currently owned by insiders.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.